Q2 2023 · 13F-HR
Knoll Capital Management, LLCholdings as filed
Filed 2023-08-15 · accession 0001104659-23-091702
$82.5M
Reported value
27
Positions
2023-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 01438T106 | ALDX | Aldeyra Therapeutics Inc | $25.3M | 30.7% | 3,015,668 | Common | SOLE |
| G11196105 | — | Biohaven Pharmactl Hldg Co L | $10.8M | 13.1% | 450,422 | Common | SOLE |
| 05337M104 | — | Avadel Pharmaceuticals Plc | $8.2M | 9.99% | 500,000 | Common | SOLE |
| 43906K100 | HOOKGBP | HOOKIPA PHARMA | $4.9M | 5.89% | 5,517,385 | Common | SOLE |
| 03828A101 | APLT | Applied Therapeutics Inc | $4.4M | 5.35% | 3,450,000 | Common | SOLE |
| 925050106 | VRNA | Verona Pharma | $4.2M | 5.13% | 200,000 | Common | SOLE |
| 92189F106 | GDX | Vaneck Gold Miners ETF | $2.8M | 3.35% | 91,850 | Common | SOLE |
| 37954Y848 | SIL | Global X Silver Miners ETF 37954Y848 | $2.3M | 2.83% | 89,700 | Common | SOLE |
| M40527109 | ENTX | Entera Bio Ltd | $2.1M | 2.54% | 2,484,275 | Common | SOLE |
| 92189F791 | GDXJ | Vaneck Junior Gold Miners ETF | $1.9M | 2.30% | 53,150 | Common | SOLE |
| 099502106 | BAH | Booz Allen Hamilton HLDG COR | $1.5M | 1.76% | 13,000 | Common | SOLE |
| 92826C839 | V | Visa | $1.2M | 1.40% | 4,850 | Common | SOLE |
| 883556102 | TMO | Thermo Fischer Scientific Inc | $1.1M | 1.33% | 2,100 | Common | SOLE |
| 67576A100 | OCUL | Ocular Therapeutix Inc. | $1.0M | 1.25% | 200,000 | Common | SOLE |
| 02209S103 | MO | Altria Group Inc | $1.0M | 1.25% | 22,700 | Common | SOLE |
| 126650100 | CVS | CVS Health Corp | $1.0M | 1.22% | 14,500 | Common | SOLE |
| 351858105 | FNV | Franco Nev Corp CAD | $998,200 | 1.21% | 7,000 | Common | SOLE |
| 828363101 | SIL1EUR | Silvercrest Metals Inc CAD | $996,200 | 1.21% | 170,000 | Common | SOLE |
| 666807102 | NOC | Northrop Grumman Corp | $986,807 | 1.20% | 2,165 | Common | SOLE |
| 68827L101 | OREUR | OSISKO GOLD ROYALTIES LTD | $969,200 | 1.17% | 400,000 | Common | SOLE |
| 68217N105 | — | Omega Therapeutics Inc. | $968,856 | 1.17% | 173,010 | Common | SOLE |
| 811916105 | SA | SEABRIDGE GOLD INC | $964,000 | 1.17% | 80,000 | Common | SOLE |
| 68619K105 | — | Orgenesis, Inc. | $882,285 | 1.07% | 634,738 | Common | SOLE |
| 67576A100 | OCUL | Ocular Therapeutix Inc. | $814,300 | 0.99% | 95,800 | CALL | SOLE |
| 02155H200 | ALT | Altimmune Inc | $613,739 | 0.74% | 173,864 | Common | SOLE |
| 67577R102 | IRD | Ocuphire Pharma Inc. | $434,000 | 0.53% | 100,000 | Common | SOLE |
| 09075P105 | BTAIEUR | BioXcell | $199,800 | 0.24% | 30,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.